<SEC-DOCUMENT>0001157523-16-004955.txt : 20160318
<SEC-HEADER>0001157523-16-004955.hdr.sgml : 20160318
<ACCEPTANCE-DATETIME>20160318172301
ACCESSION NUMBER:		0001157523-16-004955
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20160318
FILED AS OF DATE:		20160318
DATE AS OF CHANGE:		20160318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		161516969

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a51303931.htm
<DESCRIPTION>AURINIA PHARMACEUTICALS INC.
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2016 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">
      <br>
      <font style="font-size: 16pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><b><font style="font-size: 16pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 16pt"></font><font style="font-size: 16pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Washington,
      D.C. 20549</b></font>
    </p>
    <hr style="height: 1.0 pt; width: 100%; color: #000000; text-align: center">


    <p style="text-align: center">
      <font style="font-size: 14pt; font-family: Times New Roman"><b>FORM 6-K</b></font>
    </p>
    <hr style="height: 1.0 pt; width: 100%; color: #000000; text-align: center">


    <p style="text-align: center">
      <font style="font-family: Times New Roman"><b>&#160;</b></font><b><font style="font-size: 12pt; font-family: Times New Roman">REPORT
      OF FOREIGN PRIVATE ISSUER</font></b><br><font style="font-size: 12pt; font-family: Times New Roman"><b>PURSUANT
      TO RULE 13A-16 OR 15D-16 UNDER THE</b></font><br><font style="font-size: 12pt; font-family: Times New Roman"><b>SECURITIES
      EXCHANGE ACT OF 1934</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Dated</b></font><font style="font-size: 10pt; font-family: Times New Roman">
      </font><font style="font-size: 10pt; font-family: Times New Roman"><b>March
      18, 2016</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman"><b>Commission
      File Number</b></font><b> 001-36421</b>
    </p>
    <hr style="height: 1.0 pt; width: 100%; color: #000000; text-align: center">


    <p style="text-align: center">
      <font style="font-size: 24pt"><b>AURINIA PHARMACEUTICALS INC.</b></font><br><b>(Exact
      name of Registrant as specified in its charter)</b><br><br>
    </p>
    <hr style="height: 1.0 pt; width: 100%; color: #000000; text-align: center">


    <p style="text-align: center">
      <b>N/A</b><br><b>(Translation of Registrant&#8217;s Name)</b><br><br>
    </p>
    <p style="text-align: center">
      <b>#1203-4464 Markham Street</b><br><b>Victoria, British Columbia</b><br><b>V8Z7X8</b><br><b>(250)
      708-4272</b><br><b>(Address and telephone number of registrant&#8217;s
      principle executive offices)</b>
    </p>
    <p style="text-align: center">

    </p>
    <hr style="height: 1.0 pt; width: 100%; color: #000000; text-align: center">


    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark whether the registrant files or will file annual reports
      under cover of Form 20-F or Form 40-F:</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Form 20-F &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 10pt; font-family: Times New Roman">
      &#160;&#160;&#160;&#160;Form 40-F&#160; </font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8864;</font>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(1):&#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><br>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(7):&#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><br>
    </p>
    <p style="text-indent: 30.0px; text-align: justify">
      <font style="font-size: 10pt; font-family: Times New Roman">Indicate by
      check mark whether by furnishing the information contained in this Form,
      the registrant is also thereby furnishing the information to the
      Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
      of 1934.</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Yes &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8414;</font><font style="font-size: 12pt">&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: Times New Roman">
      No &#160;</font><font style="font-size: 12pt; font-family: Arial Unicode MS">&#8864;</font>
    </p>
    <p style="text-indent: 30.0px; text-align: justify">
      <font style="font-size: 10pt; font-family: Times New Roman">If &quot;Yes&quot; is
      marked, indicate below the file number assigned to the registrant in
      connection with Rule 12g3-2(b): Not a</font>pplicable.<br>
    </p>
    <div style="text-indent: 0pt; margin-right: 0pt; width: 100%; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt"><br style="font-size: 10pt; font-family: Times New Roman">
      </font><font style="font-family: Times New Roman; font-size: 10pt"><b>SIGNATURES</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-family: Times New Roman; font-size: 10pt">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized. </font>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%; margin-bottom: 10.0px">
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 6%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Dated:
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 44%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            March 18, 2016
          </p>
        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td valign="top" colspan="3" style="text-align: left; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Aurinia Pharmaceuticals Inc.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td valign="top" colspan="3" style="text-align: center; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-bottom: 2.0px; text-align: left; padding-left: 0.0px; width: 6%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-bottom: 2.0px; text-align: left; padding-left: 0.0px; width: 44%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-bottom: 2.0px; text-align: left; padding-left: 0.0px; width: 3%">
          By:
        </td>
        <td valign="top" colspan="2" style="border-bottom-width: 1.0pt; border-bottom-color: black; border-bottom-style: solid; text-align: left; padding-left: 0.0px">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ Dennis Bourgeault
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 3%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 5%">
          Name:
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 42%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Dennis Bourgeault
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 6%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 44%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 5%">
          Title:
        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 42%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Chief Financial Officer
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">

    </p>
    <div style="text-indent: 0pt; margin-right: 0pt; width: 100%; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="font-size: 10pt; font-family: Times New Roman; text-align: center">
          2
        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <b>EXHIBIT&#160;INDEX</b>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; font-family: Times New Roman; width: 100%; margin-bottom: 10.0px">
      <tr>
        <td valign="bottom" style="border-bottom-width: 1.0pt; border-bottom-color: black; border-bottom-style: solid; text-align: left; padding-left: 0.0px; width: 7%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Exhibit</b>
          </p>
        </td>
        <td valign="bottom" style="padding-bottom: 2.0px; text-align: left; padding-left: 0.0px; width: 5%">
          &#160;
        </td>
        <td valign="bottom" style="border-bottom-width: 1.0pt; border-bottom-color: black; border-bottom-style: solid; text-align: left; padding-left: 0.0px; width: 88%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Description of Exhibit</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 7%">

        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 88%">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-right: 0.0px; text-align: left; padding-left: 0.0px; width: 7%; white-space: nowrap">
          99.1
        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px; width: 88%">
          <p style="margin-top: 0px; margin-bottom: 0px">
            News Release &#8211; Aurinia Reports Fourth Quarter and Full Year 2005
            Financial Results and Recent Operational Highlights
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      3
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51303931ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2016 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Aurinia
      Reports Fourth Quarter and Full Year 2015 Financial Results and Recent
      Operational Highlights</b></font>
    </p>
    <p>
      VICTORIA, British Columbia--(BUSINESS WIRE)--March 18, 2016--Aurinia
      Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP) (&#8220;Aurinia&#8221; or the &#8220;Company&#8221;)
      has released its financial results for the fourth quarter and year ended
      December 31, 2015. Amounts, unless specified otherwise, are expressed in
      U.S. dollars.
    </p>
    <p>
      <b>Recent operational highlights</b>
    </p>
    <p>
      <b>Aura-LV (AURA) Phase 2b clinical trial update- Patient enrollment
      completed</b>
    </p>
    <p>
      On January 19, 2016, the Company announced completion of patient
      enrollment of its AURA (<u><i><b>A</b></i></u>urinia <u><i><b>U</b></i></u>rinary
      protein <u><i><b>R</b></i></u>eduction in <u><i><b>A</b></i></u>ctive
      lupus nephritis or AURA) clinical trial at 265 patients (target 258
      patients). This Phase 2b trial, is a randomized, controlled,
      double-blind study comparing the efficacy of voclosporin as a component
      of multi-targeted therapy against placebo in achieving remission in
      patients with active lupus nephritis (LN). AURA is one of the largest
      prospective registration-quality studies ever conducted within this
      specific disease area.
    </p>
    <p>
      The AURA trial has been designed to demonstrate that voclosporin can
      induce a rapid and sustained reduction of proteinuria with extremely low
      steroid exposure. The placebo-controlled trial assesses two doses of
      voclosporin, with all patients receiving background therapy of
      mycophenolate mofetil (MMF) coupled with an aggressive oral
      corticosteroid taper. There will be a primary analysis to determine
      complete remission at week 24 (confirmed at 26 weeks) and various
      secondary analyses at both 24 and 48 weeks which include biomarkers and
      markers of non-renal lupus. This disease has shown to be particularly
      difficult to treat with fewer than 20% of patients achieving clinical
      remission at six months on existing regimens which often require
      unacceptably high steroid exposure in this predominantly young, female
      population.
    </p>
    <p>
      <b>AURION study update</b>
    </p>
    <p>
      On February 8, 2016 the Company announced that it had completed a
      preliminary analysis of its AURION (<u>A</u>urinia early <u>U</u>rinary
      protein <u>R</u>educt<u>ion</u> Predicts Response) study. In the first
      seven patients that have reached at least eight weeks of therapy in the
      AURION study, 100% (7/7) have achieved at least a 25% reduction in
      proteinuria compared to study entry. A 25% reduction in proteinuria has
      been shown to be predictive of a positive clinical response at 24<sup> </sup>weeks.
      All of the other pre-specified eight week biomarkers of active lupus
      nephritis (LN) have also improved and are trending towards
      normalization. These biomarkers have also been shown to be predictive of
      positive clinical response rates at 24 weeks.
    </p>
    <p>
      In the first eight weeks of a 48 week regimen of multi-target therapy
      including voclosporin in AURION, an overall mean reduction of
      proteinuria of 72% compared to pre-treatment levels was observed, and
      57% (4/7) of these patients achieved complete remission as defined by a
      urinary protein creatinine ratio of &#8804; 0.5mg/mg. Overall renal function
      as measured by eGFR in these patients has remained stable.
    </p>
    <p>
      The AURION study is an open label, single arm, exploratory study
      assessing the ability of biomarkers at 8 weeks to predict clinical
      response rates at 24 and 48 weeks in subjects taking voclosporin 23.7mg
      twice daily in combination with standard of care, mycophenolate mofetil
      and corticosteroids, in patients with active LN. It is the first ever
      trial with voclosporin in this patient population and supports the
      Company&#8217;s hypothesis that utilizing a multi-targeted approach with
      voclosporin may help LN patients.
    </p>
    <div style="text-indent: 0pt; margin-right: 0pt; width: 100%; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>FDA Fast Track</b>
    </p>
    <p>
      On March 2, 2016 the Company announced that the U.S. Food and Drug
      Administration (FDA) granted Fast Track designation for <i>voclosporin</i>,
      the Company&#8217;s next generation calcineurin inhibitor, for the treatment
      of LN.
    </p>
    <p>
      The Fast Track program was created by the FDA to facilitate the
      development and expedite the review of new drugs that are intended to
      treat serious or life-threatening conditions and that demonstrate the
      potential to address significant unmet medical needs. Compounds that
      receive this FDA designation benefit from more frequent meetings and
      communications with the FDA to review the drug&#8217;s development plan
      including the design of clinical trials and the use of biomarkers to
      support approval. Additionally, Fast Track designation allows the
      Company to submit parts of the New Drug Application (NDA) on a rolling
      basis for review as data becomes available. The Company expects to
      analyse and review the AURA data with the FDA later in 2016 in order to
      determine the appropriate next steps.
    </p>
    <p>
      <b>Looking forward &#8211; Expected upcoming milestone</b>
    </p>
    <p>
      Un-blinding and disclosure of the primary AURA trial data is scheduled
      within approximately one month of the last enrolled patient completing
      24 weeks of active treatment. Therefore, the Company expects that the
      primary end-point results of the AURA trial will be released in the
      third quarter ended September 30, 2016.
    </p>
    <p>
      <b>Financial results for the year ended December 31, 2015</b>
    </p>
    <p>
      The Company made significant progress with its ongoing AURA trial in
      2015 with patient enrollment completed early in 2016. Activities focused
      on the recruitment, enrollment and treatment of patients with lupus
      nephritis (LN). Over 90 sites are set up in 20 countries worldwide. The
      Company also made progress with its AURION study in Malaysia with eight
      week data released on the first seven patients as noted above.
    </p>
    <p>
      For the year ended December 31, 2015, the Company recorded a
      consolidated net loss of $18.6 million or $0.58 per common share, as
      compared to a consolidated net loss of $19.4 million or $0.67 per common
      share in 2014.
    </p>
    <p>
      The change was primarily attributable to an increase of $6.9 million in
      research and development costs offset by a change of $7.9 million in the
      derivative warrant liability to a gain of $5.1 million for the year
      ended December 31, 2015 compared to a loss of $2.8 million in 2014. In
      addition the 2014 comparative figure reflected a gain on
      extinguishment/re-measurement of warrant liability of $2.8 million.
      There was no similar item in 2015.
    </p>
    <p>
      After adjusting for the non-cash impact of the revaluation of the
      derivative warrant liability, the net loss from operations for the year
      ended December 31, 2015 was $23.7 million compared to $16.6 million for
      the corresponding period in 2014.
    </p>
    <p>
      The Company incurred net research and development expenditures of $16.0
      million for the year ended December 31, 2015, as compared to $9.1
      million for the same period in 2014. Research and development
      expenditures increased year over year as the number of patients enrolled
      in the trial increased substantially in 2015. Research and development
      expenditures in 2015 reflected higher costs related primarily to drug
      distribution, patient recruitment, enrollment and treatment activities
      associated with the AURA trial compared to the same period in 2014. AURA
      trial costs are forecast to decrease in 2016 as patients complete the
      trial.
    </p>
    <p>
      The Company incurred corporate, administration and business development
      expenditures of $6.3 million for the year ended December 31, 2015, as
      compared with $6.9 million for the same period in fiscal 2014.
      Corporate, administration and business development expense in 2015
      included $2.4 million of non-cash stock option compensation expense
      related to the issuance of stock options compared to $1.9 million of
      non-cash stock option compensation expense in 2014.
    </p>
    <div style="text-indent: 0pt; margin-right: 0pt; width: 100%; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      Other expense (income) reflected expense of $128,000 for the year ended
      December 31, 2015 compared to other income of $1.7 million for 2014. The
      change was primarily due to the Company recording in 2014 a non-cash
      gain of $2.8 million on extinguishment and re-measurement of warrant
      liability initially recorded upon the completion of the private
      placement on February 14, 2014. There was no similar item in 2015. The
      Company also recorded as other expense, a revaluation adjustment on
      contingent consideration to ILJIN Life Science Co., Ltd. in the amount
      of $337,000 in 2015 compared to $848,000 in 2014.
    </p>
    <p>
      <b>Financial results for the fourth quarter ended December 31, 2015</b>
    </p>
    <p>
      The Company reported a consolidated net loss of $4.1 million or $0.13
      per common share for the three months ended December 31, 2015, as
      compared to a consolidated net loss of $6.4 million or $0.20 per common
      share for the three months ended December 31, 2014.
    </p>
    <p>
      The decrease in the consolidated net loss was primarily attributable to
      recording a fair value adjustment gain on derivative warrant liability
      of $1.5 million in the fourth quarter of 2015 versus of loss of $1.4
      million in the comparable period in 2014.
    </p>
    <p>
      Research and development expenditures increased to $3.7 million in the
      fourth quarter of 2015, compared to $3.1 million in the fourth quarter
      of 2014 resulting from the progression of the AURA trial and the AURION
      study during 2015.
    </p>
    <p>
      Corporate and administration expenses were $1.6 million for the fourth
      quarter of 2015, compared to $1.4 million for the fourth quarter of 2014.
    </p>
    <p>
      <b>Financial Liquidity</b>
    </p>
    <p>
      The Company had cash, cash equivalents and short term investments of
      $15.8 million as at December 31, 2015. Aurinia believes its financial
      resources should be sufficient to finance the AURA trial, the AURION
      study and corporate costs until approximately December 31, 2016.
      However, future cash requirements could vary from current estimates due
      to a number of factors including the costs associated with its AURA
      trial.
    </p>
    <p>
      The audited financial statements and the Management's Discussion and
      Analysis for the year ended December 31, 2015, are accessible on
      Aurinia's website at <u>www.auriniapharma.com</u> or on SEDAR at <u>www.sedar.com</u>
      or on EDGAR at <u>www.sec.gov/edgar</u>.
    </p>
    <p>
      <i><b>About Aurinia</b></i>
    </p>
    <p>
      Aurinia is a clinical stage pharmaceutical company focused on the global
      nephrology market. The fully-enrolled AURA clinical trial is evaluating
      the efficacy of its lead drug, voclosporin, as a treatment for active
      LN. LN is an inflammation of the kidneys, that if inadequately treated
      can lead to end-stage renal disease, making LN a serious and potentially
      life-threatening condition.
    </p>
    <p>
      Voclosporin is a novel and potentially best-in-class calcineurin
      inhibitor (&#8220;CNI&#8221;) with extensive clinical data in over 2,000 patients in
      other indications. Voclosporin is made by a modification of a single
      amino acid of the cyclosporine molecule (a CNI approved for use in
      transplant patients since 1983). This modification results in a more
      predictable pharmacokinetic and pharmacodynamic relationship, an
      increase in potency vs. cyclosporine, an altered metabolic profile, and
      potential for flat dosing.
    </p>
    <div style="text-indent: 0pt; margin-right: 0pt; width: 100%; margin-left: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>About AURA:</b>
    </p>
    <p>
      The AURA trial is an adequate and well-controlled clinical trial that
      enrolled 265 patients and is being conducted in over 20 countries
      worldwide. This trial will compare the efficacy of voclosporin against
      placebo in achieving remission in patients with active lupus nephritis.
      The AURA trial designed to demonstrate that voclosporin can induce a
      rapid and sustained reduction of proteinuria in the presence of
      extremely low steroid exposure. It will compare two dosage groups of
      voclosporin (23.7mg and 39.5mg) compared to placebo, with all patients
      receiving mycophenolate mofetil (MMF) and oral corticosteroids as
      background therapy. There will be a primary analysis to determine
      complete remission at week 24 (confirmed at 26 weeks) and various
      secondary analyses at week 48 which include biomarkers and markers of
      non-renal SLE.
    </p>
    <p>
      <b>About AURION:</b>
    </p>
    <p>
      The AURION study is an open label, exploratory study being conducted at
      two sites in Malaysia to assess the short term predictors of response
      using voclosporin (23.7mg) in combination with mycophenolate mofetil and
      oral corticosteroids in patients with active lupus nephritis. This study
      will examine biomarkers of disease activity at 8 weeks and their ability
      to predict response at 24 and 48 weeks.
    </p>
    <p>
      <i>We seek Safe Harbor</i>.
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br>Aurinia Pharmaceuticals Inc.<br>Mr. Michael Martin,
      250-708-4272<br>Chief Operating Officer<br>Fax: 250-744-2498<br>mmartin@auriniapharma.com<br>or<br>Mr.
      Dennis Bourgeault, 780-643-2260<br>Chief Financial Officer<br>Fax:
      780-484-4105<br><u>dbourgeault@auriniapharma.com</u>
    </p>
    <p>

    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
